文章：

颅内乳腺癌转移的立体定向放射外科治疗：一项系统性回顾与荟萃分析

Stereotactic Radiosurgery for Intracranial Breast Metastases: A Systematic Review and Meta-Analysis

原文发布日期：21 October 2024

DOI: 10.3390/cancers16203551

类型: Article

开放获取: 是

英文摘要：

Background/Objectives: To determine the impact of stereotactic radiosurgery on outcomes of metastatic breast cancer with intracranial metastases. Methods: We systematically searched the PubMed and EMBASE databases for studies published between 1 January 1990 and 1 August 2024. Primary research articles evaluating the outcomes of stereotactic radiosurgery on intracranial metastases from breast cancer were included. Adverse events were defined as leptomeningeal disease, radiation necrosis, seizure, and headache. The pooled estimate was calculated using the DerSimonian and Laird approach. Results: Sixteen studies encompassing 1228 patients met the inclusion criteria. Our analysis revealed a median survival duration of 13.1 ± 3.8 months and a pooled 1-year overall survival rate of 53.1% after SRS treatment. There was a 29% local recurrence rate at 1 year and a 35% overall distant recurrence rate. In addition, our analysis found a relatively low rate of acute adverse events at 15.5%. Conclusions: SRS demonstrates promising efficacy and safety in managing intracranial metastases from breast cancer, with a favorable toxicity profile.

摘要翻译： 

背景/目的：旨在评估立体定向放射外科治疗对乳腺癌颅内转移患者预后的影响。方法：我们系统检索了PubMed和EMBASE数据库中1990年1月1日至2024年8月1日发表的相关研究。纳入所有评估立体定向放射外科治疗乳腺癌颅内转移疗效的原始研究文献。不良事件定义为软脑膜疾病、放射性坏死、癫痫发作及头痛。采用DerSimonian和Laird方法计算合并效应量。结果：共16项研究符合纳入标准，涉及1228例患者。分析显示立体定向放射外科治疗后中位生存期为13.1±3.8个月，合并1年总生存率为53.1%。1年局部复发率为29%，总体远处复发率为35%。此外，分析发现急性不良事件发生率相对较低，为15.5%。结论：立体定向放射外科在治疗乳腺癌颅内转移方面展现出良好的疗效和安全性，具有理想的毒性特征。

原文链接：

Stereotactic Radiosurgery for Intracranial Breast Metastases: A Systematic Review and Meta-Analysis